Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 2/20 | 0.42 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16837188 | 0.85 | PGR (0.40) | AVPR1BIP6K1PGRNR3C2NR3C1 | |
| SCHEMBL1788080 | 0.85 | PGR (0.40) | AVPR1BIP6K1PGRNR3C2NR3C1 | |
| SCHEMBL1479564 | 0.85 | AVPR1B (0.39) | AVPR1BIP6K1PGRNR3C2NR3C1 | |
| SCHEMBL12847934 | 0.84 | ALDH1A1 (0.46) | KMT2ATP53ATMBRD4MEN1 | |
| SCHEMBL1590714 | 0.84 | IDO1 (0.45) | IP6K1PGRKMT2ATP53BRD4 | |
| SCHEMBL1480710 | 0.84 | KMT2A (0.39) | IP6K1KMT2ATP53ATMBRD4 | |
| SCHEMBL75146 | 0.84 | KMT2A (0.50) | AVPR1BPGRKMT2ATP53TRPV4 | |
| SCHEMBL16837199 | 0.83 | IP6K1 (0.41) | AVPR1BIP6K1PGRNR3C2NR3C1 | |
| SCHEMBL1479795 | 0.83 | IP6K1 (0.41) | AVPR1BIP6K1PGRNR3C2NR3C1 | |
| SCHEMBL1588379 | 0.82 | IP6K1 (0.38) | AVPR1BIP6K1PGRKMT2AHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362394-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABBVIE DEUTSCHLAND (DE) | 2016-12-15 | — | — | US | disclosed |
| US-9422264-B2 | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9403796-B2 | Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-02 | — | — | US | disclosed |
| US-20150352110-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2015-12-10 | — | — | US | disclosed |
| US-20140378471-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2014-12-25 | — | — | US | disclosed |
| US-20140315914-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-23 | — | — | US | disclosed |
| US-8859557-B2 | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20140275110-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-8815868-B2 | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-2114923-B1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO KG (DE) | 2014-08-06 | — | — | EP | disclosed |
| WO-2010009775-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG (DE) | 2010-01-28 | — | — | WO | disclosed |
| EP-2114921-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR LIGAND | Abbott GmbH & Co. KG (DE) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114923-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114922-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR MODULATOR | Abbott GmbH & Co. KG (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009071687-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071691-A2 | OXINDOLE DERIVATIVES AND THE USE THEREOF AS A MEDICATION | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008080971-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR LIGAND | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080970-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR LIGAND | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080972-A1 | SUBSTITUTED OXINDOLE DERIVATIVE AND ITS USE AS A VASOPRESSIN RECEPTOR MODULATOR | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080973-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378471-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885IP6K1 2964/4885PGR 548/4885 |
| US-20160362394-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885IP6K1 2824/4885PGR 1934/4885 |
| US-20150352110-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885IP6K1 2964/4885PGR 548/4885 |
| US-20140315914-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885IP6K1 2824/4885PGR 1934/4885 |
| US-20140275110-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885IP6K1 2918/4885PGR 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.